Zaofeng Yang

6PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)BiomaterialsMedical infection agents (incl. prions)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 16, 2026
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.

|Jul 22, 2026
Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models.

|Feb 12, 2026
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.

Zaofeng Yang, Jongwon Im, Noah Chen

|Oct 18, 2024
Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms.

Fangda Li, Zaofeng Yang, Thomas M Savage

|Sep 06, 2024
A Targeted and Protease-Activated Genetically Encoded Melittin-Containing Particle for the Treatment of Cutaneous and Visceral Leishmaniasis.

Madiha Habib, Jiale Zheng, Chin-Fung Chan

|Sep 14, 2022
Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.

Zaofeng Yang, Jacquelyne Ka-Li Sun, Marianne M Lee

Pageof 1

Frequent Collaborators

4 joint publications

Nicholas Arpaia

3 joint publications

Fangda Li

3 joint publications

Kenia de Los Santos-Alexis

3 joint publications

Dylan L Mariuzza